Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123746824> ?p ?o ?g. }
- W2123746824 endingPage "385" @default.
- W2123746824 startingPage "377" @default.
- W2123746824 abstract "Background Long-term complications of cystic fibrosis include osteoporosis and fragility fractures, but few data are available about effective treatment strategies, especially in young patients. We investigated treatment of low bone mineral density in children, adolescents, and young adults with cystic fibrosis. Methods We did a multicentre trial in two phases. We enrolled patients aged 5–30 years with cystic fibrosis and low bone mineral density, from ten cystic fibrosis regional centres in Italy. The first phase was an open-label, 12-month observational study of the effect of adequate calcium intake plus calcifediol. The second phase was a 12-month, double-blind, randomised, placebo-controlled, parallel group study of the efficacy and safety of oral alendronate in patients whose bone mineral apparent density had not increased by 5% or more by the end of the observational phase. Patients were randomly assigned to either alendronate or placebo. Both patients and investigators were masked to treatment assignment. We used dual x-ray absorptiometry at baseline and every 6 months thereafter, corrected for body size, to assess lumbar spine bone mineral apparent density. We assessed bone turnover markers and other laboratory parameters every 3–6 months. The primary endpoint was mean increase of lumbar spine bone mineral apparent density, assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01812551. Findings We screened 540 patients and enrolled 171 (mean age 13·8 years, SD 5·9, range 5–30). In the observational phase, treatment with calcium and calcifediol increased bone mineral apparent density by 5% or more in 43 patients (25%). 128 patients entered the randomised phase. Bone mineral apparent density increased by 16·3% in the alendronate group (n=65) versus 3·1% in the placebo group (n=63; p=0·0010). 19 of 57 young people (33·3%) receiving alendronate attained a normal-for-age bone mineral apparent density Z score. In the observational phase, five patients had moderate episodes of hypercalciuria, which resolved after short interruption of calcifediol treatment. During the randomised phase, one patient taking alendronate had mild fever versus none in the placebo group; treatment groups did not differ significantly for other adverse events. Interpretation Correct calcium intake plus calcifediol can improve bone mineral density in some young patients with cystic fibrosis. In those who do not respond to calcium and calcifediol alone, alendronate can safely and effectively increase bone mineral density. Funding Telethon Foundation (Italy)." @default.
- W2123746824 created "2016-06-24" @default.
- W2123746824 creator A5001205671 @default.
- W2123746824 creator A5006071995 @default.
- W2123746824 creator A5006141192 @default.
- W2123746824 creator A5009932606 @default.
- W2123746824 creator A5014173268 @default.
- W2123746824 creator A5017644925 @default.
- W2123746824 creator A5018709296 @default.
- W2123746824 creator A5018991397 @default.
- W2123746824 creator A5021298112 @default.
- W2123746824 creator A5024886659 @default.
- W2123746824 creator A5027769276 @default.
- W2123746824 creator A5030768403 @default.
- W2123746824 creator A5036082730 @default.
- W2123746824 creator A5037732667 @default.
- W2123746824 creator A5041278343 @default.
- W2123746824 creator A5045455455 @default.
- W2123746824 creator A5053326821 @default.
- W2123746824 creator A5063502705 @default.
- W2123746824 creator A5065371441 @default.
- W2123746824 creator A5070368628 @default.
- W2123746824 creator A5070963688 @default.
- W2123746824 creator A5074177015 @default.
- W2123746824 creator A5089697692 @default.
- W2123746824 date "2013-07-01" @default.
- W2123746824 modified "2023-09-24" @default.
- W2123746824 title "Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate" @default.
- W2123746824 cites W1980550139 @default.
- W2123746824 cites W1981855172 @default.
- W2123746824 cites W1998318247 @default.
- W2123746824 cites W2002468342 @default.
- W2123746824 cites W2004101195 @default.
- W2123746824 cites W2017165492 @default.
- W2123746824 cites W2021194949 @default.
- W2123746824 cites W2036125852 @default.
- W2123746824 cites W2037778256 @default.
- W2123746824 cites W2044178924 @default.
- W2123746824 cites W2056598822 @default.
- W2123746824 cites W2062195589 @default.
- W2123746824 cites W2066322090 @default.
- W2123746824 cites W2069609459 @default.
- W2123746824 cites W2069802420 @default.
- W2123746824 cites W2077007000 @default.
- W2123746824 cites W2077291356 @default.
- W2123746824 cites W2078131192 @default.
- W2123746824 cites W2080089180 @default.
- W2123746824 cites W2080418949 @default.
- W2123746824 cites W2091685857 @default.
- W2123746824 cites W2109043207 @default.
- W2123746824 cites W2125230559 @default.
- W2123746824 cites W2132295623 @default.
- W2123746824 cites W2141780505 @default.
- W2123746824 cites W2160295774 @default.
- W2123746824 cites W2161446399 @default.
- W2123746824 cites W2162274997 @default.
- W2123746824 cites W3121063299 @default.
- W2123746824 cites W4365787127 @default.
- W2123746824 doi "https://doi.org/10.1016/s2213-2600(13)70064-x" @default.
- W2123746824 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24429202" @default.
- W2123746824 hasPublicationYear "2013" @default.
- W2123746824 type Work @default.
- W2123746824 sameAs 2123746824 @default.
- W2123746824 citedByCount "33" @default.
- W2123746824 countsByYear W21237468242013 @default.
- W2123746824 countsByYear W21237468242014 @default.
- W2123746824 countsByYear W21237468242015 @default.
- W2123746824 countsByYear W21237468242016 @default.
- W2123746824 countsByYear W21237468242017 @default.
- W2123746824 countsByYear W21237468242018 @default.
- W2123746824 countsByYear W21237468242019 @default.
- W2123746824 countsByYear W21237468242020 @default.
- W2123746824 countsByYear W21237468242021 @default.
- W2123746824 countsByYear W21237468242022 @default.
- W2123746824 countsByYear W21237468242023 @default.
- W2123746824 crossrefType "journal-article" @default.
- W2123746824 hasAuthorship W2123746824A5001205671 @default.
- W2123746824 hasAuthorship W2123746824A5006071995 @default.
- W2123746824 hasAuthorship W2123746824A5006141192 @default.
- W2123746824 hasAuthorship W2123746824A5009932606 @default.
- W2123746824 hasAuthorship W2123746824A5014173268 @default.
- W2123746824 hasAuthorship W2123746824A5017644925 @default.
- W2123746824 hasAuthorship W2123746824A5018709296 @default.
- W2123746824 hasAuthorship W2123746824A5018991397 @default.
- W2123746824 hasAuthorship W2123746824A5021298112 @default.
- W2123746824 hasAuthorship W2123746824A5024886659 @default.
- W2123746824 hasAuthorship W2123746824A5027769276 @default.
- W2123746824 hasAuthorship W2123746824A5030768403 @default.
- W2123746824 hasAuthorship W2123746824A5036082730 @default.
- W2123746824 hasAuthorship W2123746824A5037732667 @default.
- W2123746824 hasAuthorship W2123746824A5041278343 @default.
- W2123746824 hasAuthorship W2123746824A5045455455 @default.
- W2123746824 hasAuthorship W2123746824A5053326821 @default.
- W2123746824 hasAuthorship W2123746824A5063502705 @default.
- W2123746824 hasAuthorship W2123746824A5065371441 @default.
- W2123746824 hasAuthorship W2123746824A5070368628 @default.
- W2123746824 hasAuthorship W2123746824A5070963688 @default.
- W2123746824 hasAuthorship W2123746824A5074177015 @default.